Today a rumor relayed by Bloomberg allegued that "Genfit (GNFTF) is working with advisers to explore a sale, licensing agreements or partnerships »
The only news is that GENFIT is working with advisers, otherwise we all knew for month, that GENFIT was exploring licensing agreements or partnerships and is open to a sale if the offer is very generous, it was told months ago by the CEO himself.
So where are the news ?
Maybe it means that negotiations are close to finish ?
In my opinion it is a little bit too early for a deal but one can explain the rumor and the beginning of recovery of the GENFIT's massacred value.
What are the facts !
§ GENFIT own alone all the rights on Elafibranor until 2035
§ Elafibranor is one of the two leaders in potential NASH treatment (with OCA)
§ Elafibranor is safe ( allowed in pediatric trial)
§ Elafibranor can reach the market in 2019 through a subpart H agreement
§ Elafibranor is backed with the most advanced diagnosis biomarker program also owned by GENFIT
§ Elafibranor is Cardioprotector
§ Elfibranor is acting on insulino resistance
§ Elefibranor is the only drug which demonstrated a significant NASH reversion in a controlled trial.
§ A prospective article published in NATURE is giving 30% of the NASH Market to elafibranor by 2025.
§ Genfit's cash is enough to reach the Phase 3 intermediate results and the subpart H
All is green, that is the truth !
There is no hurry for GENFIT to make a deal !
The company value is very very low ( 1/5 of INTERCEPT value)
In my opinion, no deal should be concluded under 5 Billions and 10 billions is closer to the fair value.
So the value need a big recovery before a deal,
Rumors are not always true but can help !
And it is still a very good investment opportunity !
